In addition, multiple MSLN-directed antibody-drug conjugates (ADCs) have been developed, and some clinical trials have shown good tolerance and preliminary evidence of antitumor activity in ovarian cancer (149, 150, 151). This evidence concerns the gene MSLN and ovarian cancer.